To determine the performance of the clinical-grade CCR5 RO assay, we obtained blinded clinical samples from eight participants enrolled in a phase 2, two-arm, randomized, double blind, placebo-controlled study on the effects of Leronlimab treatment in long COVID-19 (ClinicalTrials.gov Identifier: NCT04678830). Here, CCR5 is linked to COVID-19.